Skip to main content
. 2021 Nov 5;12:6428. doi: 10.1038/s41467-021-26019-y

Fig. 5. A view to the future.

Fig. 5

Top graphic represents the current treatment paradigm: patients with HER2+ breast cancer as determined by IHC or FISH receive the same neoadjuvant chemotherapy and HER2-directed therapy. Bottom graphic illustrates how implementation of the RPPA assay and gene expression profiling following positive IHC or FISH will enable de-escalation or escalation of chemotherapy and HER2-directed therapy. Original illustration: A. Haymond.